Print Friendly, PDF & Email

NCT/Study#

NCT02635672 /

VNC-152-101

An Open-Label, Multicenter Phase I Dose Escalation Study To Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics And Maximum Tolerated Dose Of VIP152 (BAY 1251152) In Subjects With Advanced Cancer

DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: